DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 191,900 shares, a drop of 8.4% from the January 15th total of 209,500 shares. Based on an average trading volume of 103,200 shares, the days-to-cover ratio is currently 1.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of DiaMedica Therapeutics in a report on Friday, November 15th.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of DiaMedica Therapeutics during the third quarter valued at $40,000. Balyasny Asset Management L.P. bought a new position in shares of DiaMedica Therapeutics during the fourth quarter valued at $79,000. Y Intercept Hong Kong Ltd bought a new position in shares of DiaMedica Therapeutics during the fourth quarter valued at $81,000. Raymond James Financial Inc. bought a new position in shares of DiaMedica Therapeutics during the fourth quarter valued at $83,000. Finally, Bank of Montreal Can bought a new position in shares of DiaMedica Therapeutics during the fourth quarter valued at $84,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Trading Up 0.6 %

DMAC traded up $0.04 during trading on Monday, reaching $6.29. The stock had a trading volume of 61,408 shares, compared to its average volume of 75,175. The stock’s 50 day moving average is $5.68 and its two-hundred day moving average is $4.75. The company has a market capitalization of $268.96 million, a price-to-earnings ratio of -11.23 and a beta of 1.46. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.45.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.